Literature DB >> 25413371

Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment.

Michael Soyka1.   

Abstract

Maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Clinical studies indicate that about a third of patients in opioid maintenance therapy show increased alcohol consumption and alcohol use disorders. Comorbid alcohol use disorders have been identified as a risk factor for clinical outcome and can cause poor physical and mental health, including liver disorders, noncompliance, social deterioration and increased mortality risk. The effects of opioid maintenance therapy on alcohol consumption are controversial and no clear pattern has emerged. Most studies have not found a change in alcohol use after initiation of maintenance therapy. Methadone and buprenorphine appear to carry little risk of liver toxicity, but further research on this topic is required. Recent data indicate that brief intervention strategies may help reduce alcohol intake, but the existing evidence is still limited. This review discusses further clinical implications of alcohol use disorders in opioid dependence.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25413371     DOI: 10.1159/000363232

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  31 in total

Review 1.  Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.

Authors:  Katie Witkiewitz; Kevin E Vowles
Journal:  Alcohol Clin Exp Res       Date:  2018-02-06       Impact factor: 3.455

2.  Psycho-Social Correlates of Opioid Use Disorder among the US Adult Population: Evidence from the National Survey on Drug Use and Health, 2015-2018.

Authors:  Mohammad Rifat Haider; Monique J Brown; Rajat Das Gupta; Sabrina Karim; Bankole Olatosi; Xiaoming Li
Journal:  Subst Use Misuse       Date:  2020-07-07       Impact factor: 2.164

3.  Opioid Misuse as a Predictor of Alcohol Treatment Outcomes in the COMBINE Study: Mediation by Medication Adherence.

Authors:  Katie Witkiewitz; Victoria R Votaw; Kevin E Vowles; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2018-06-09       Impact factor: 3.455

4.  Increasing availability of illicit and prescription opioids among people who inject drugs in a Canadian setting, 2010-2014.

Authors:  Joel Ho; Kora DeBeck; M-J Milloy; Huiru Dong; Evan Wood; Thomas Kerr; Kanna Hayashi
Journal:  Am J Drug Alcohol Abuse       Date:  2017-10-19       Impact factor: 3.829

5.  Prevalence of Heavy Alcohol Use Among People Receiving Methadone Following Change to Methadose.

Authors:  Jan Klimas; Evan Wood; Ekaterina Nosova; M-J Milloy; Thomas Kerr; Kanna Hayashi
Journal:  Subst Use Misuse       Date:  2017-06-12       Impact factor: 2.164

6.  Alcohol use disorder and motives for prescription opioid misuse: A latent class analysis.

Authors:  Victoria R Votaw; R Kathryn McHugh; Katie Witkiewitz
Journal:  Subst Use Misuse       Date:  2019-05-07       Impact factor: 2.164

7.  Factors associated with discontinuation of methadone maintenance therapy (MMT) among persons who use alcohol in Vancouver, Canada.

Authors:  Jan Klimas; Ekaterina Nosova; Eugenia Socías; Seonaid Nolan; Rupinder Brar; Kanna Hayashi; M-J Milloy; Thomas Kerr; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2018-03-23       Impact factor: 4.492

8.  The Impact of Enrolment in Methadone Maintenance Therapy on Initiation of Heavy Drinking among People Who Use Heroin.

Authors:  Jan Klimas; Evan Wood; Paul Nguyen; Huiru Dong; Michael John Milloy; Thomas Kerr; Kanna Hayashi
Journal:  Eur Addict Res       Date:  2016-04-06       Impact factor: 3.015

9.  Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting.

Authors:  Huiru Dong; Kanna Hayashi; M-J Milloy; Kora DeBeck; Joel Singer; Hubert Wong; Evan Wood; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2020-04-25       Impact factor: 4.492

Review 10.  Neuroimmune signaling in alcohol use disorder.

Authors:  Emma K Erickson; Emily K Grantham; Anna S Warden; R A Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-12-24       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.